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Background Creatine kinase (CK) is an enzyme found in skel-
etal muscles, myocardium and brain (CK–MM, CK–MB,
and CK–BB isoenzymes respectively). In these tissues with
high energy requirements, CK catalyses conversion of
phosphocreatine to creatine, generating adenosine triphos-
phate. Elevated CK–MM is considered a marker of muscle
damage. In the past, CK has been used to differentiate
between myopathic and neurogenic disease, higher CK being
associated with myopathic disease. It is now recognised that
CK may be mildly to moderately elevated in patients with
amyotrophic lateral sclerosis (ALS). An obvious explanation of
raised CK in ALS is striate muscle atrophy resulting from
degeneration of the subserving motor neurons. Another pos-
sible explanation is upregulation of this enzyme to provide an
energy substrate in a hypercatabolic condition. The reason
that CK elevation occurs in only a proportion of ALS cases,
the precise cause and its behaviour with disease progression is
unknown.
Objectives To determine:
1. Are ALS patients with raised CK any different from
patients with normal CK?
2. What are the implications of raised CK on disease
outcome or prognosis?
3. Does CK mirror disease progression or activity and, if
so, can it be used to monitor disease progression or
response to therapeutic interventions?
4. Can the magnitude of muscle enzyme release be used to
predict the magnitude of muscle functional impairment?
Methodology This is an observational cohort study, using the
clinical database from the Olesoxime (TRO19622) investiga-
tional medicinal product trial. This trial involving 512
patients with ALS was conducted across 15 European centres
(2009–2011). The patients were followed up at 3 monthly
intervals for 18 months while monitoring various biochemical
and haematological parameters, including CK. The steering
committee of TROPHOS (the pharmaceutical company devel-
oping Olesoxime) kindly provided the database from the
Olesoxime trial to conduct this study.
Results Baseline CK was raised in 52% of the participants
with mean CK±SD being 257±239 IU/L. Mean CK in male
participants was signiﬁcantly higher than in females
(p<0.001). Mean CK was signiﬁcantly higher amongst parti-
cipants with limb onset ALS compared to participants with
bulbar onset ALS (p<0.001). There was no signiﬁcant differ-
ence in CK levels between upper limb and lower limb onset
disease (p=0.746). Higher CK was associated with signiﬁ-
cantly better survival, even when adjusted for prognostic co–
variants (P=0.005).
Conclusions CK level is a prognostic factor for survival in
ALS, independent of its association with site of disease onset.
This ﬁnding suggests that CK may be involved in a defence
mechanism. CK levels cannot be used to predict the disease
severity or manual muscle scores at any time point. This
study highlights the usefulness of CK as a prognostic marker
in ALS.
10 of 95 J Neurol Neurosurg Psychiatry 2013;84:e2
ABN Abstracts
group.bmj.com on January 14, 2016 - Published by http://jnnp.bmj.com/Downloaded from 
AMYOTROPHIC LATERAL SCLEROSIS
BETTER PROGNOSIS IN PATIENTS WITH 
ELEVATED CREATINE KINASE SUGGESTS
and Pamela Shaw
Muhammad Rafiq, Ellen Lee, Michael Bradburn, Christopher McDermott
doi: 10.1136/jnnp-2013-306573.22
2013 84: e2 J Neurol Neurosurg Psychiatry 
 http://jnnp.bmj.com/content/84/11/e2.135
Updated information and services can be found at: 
These include:
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (1848)Drugs: CNS (not psychiatric)
 (509)Spinal cord
 (1253)Neuromuscular disease
 (282)Motor neurone disease
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 14, 2016 - Published by http://jnnp.bmj.com/Downloaded from 
